TLDR:
- QHeart Medical is presenting at Venture & Capital 2024 in Sydney to showcase their revolutionary heart and renal assist therapy for acute heart failure.
- They have received funding from the Australian government and are seeking additional investors to fund the completion of development and pre-market clinical trials.
QHeart Medical, a Brisbane-based cardiovascular device company, is making waves in the medical industry with their innovative approach to addressing acute decompensated heart failure. With over 1.25 million emergency hospitalizations for this condition in the USA alone, the need for effective therapy is critical. QHeart’s TARR device, designed to support heart and kidney dysfunction and reduce mortality rates, has shown promising results in pulse pressure and systolic blood pressure reductions. The company’s CEO & CTO, Dr. Peter Walsh, highlighted the potential impact of their technology at the Venture & Capital 2024 event in Sydney.
Thanks to funding from a CRC Project Grant by the Australian government, QHeart has been able to achieve technical proof of concept for their device. Now, they are seeking additional investors to support the completion of development and pre-market clinical trials. By presenting at the Venture & Capital 2024 event, QHeart aims to attract high-net-worth VCs, Family Offices, and professional investors who understand the potential of their disruptive technology.
Wholesale Investor’s mission to empower innovation aligns well with QHeart’s goals, making the Venture & Capital 2024 event an ideal platform for connecting with potential supporters. With a focus on private markets and small-cap opportunities, this conference provides a unique opportunity for QHeart Medical to showcase their technology and secure the funding needed to bring their TARR device to market.
For more information about QHeart Medical and the Venture & Capital 2024 event, visit their website at www.qheartmedical.com and Venture & Capital 2024.
